Yongmei Yin

机构：Jiangsu Province Hospital, Nanjing Medical University · ORCID：0000-0003-3335-369X

发表论文 298 篇 · 总被引 7337 次 · h-index 43

代表论文

• Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial (2025 · Nature Medicine · 被引 53)
• Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials (2025 · Nature Medicine · 被引 48)
• Enhanced the Trans‐Cleavage Activity of CRISPR‐Cas12a Using Metal‐Organic Frameworks as Stimulants for Efficient Electrochemical Sensing of Circulating Tumor DNA (2025 · Advanced Science · 被引 28)
• Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies (2025 · Journal of Hematology & Oncology · 被引 23)
• NSUN2-mediated m5C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis (2025 · Cancer Letters · 被引 11)
• Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. (2025 · Journal of Clinical Oncology · 被引 11)